1. Home
  2. MNSB vs RCEL Comparison

MNSB vs RCEL Comparison

Compare MNSB & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

N/A

Current Price

$21.51

Market Cap

140.1M

Sector

Finance

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.52

Market Cap

114.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNSB
RCEL
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.1M
114.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MNSB
RCEL
Price
$21.51
$3.52
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$11.75
AVG Volume (30 Days)
34.8K
201.4K
Earning Date
01-26-2026
11-06-2025
Dividend Yield
1.87%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$69,367,000.00
$72,401,000.00
Revenue This Year
$23.19
$13.12
Revenue Next Year
$2.92
$27.56
P/E Ratio
N/A
N/A
Revenue Growth
9.71
20.59
52 Week Low
$15.00
$3.33
52 Week High
$22.98
$14.16

Technical Indicators

Market Signals
Indicator
MNSB
RCEL
Relative Strength Index (RSI) 78.91 37.63
Support Level $19.68 $3.33
Resistance Level $21.44 $3.58
Average True Range (ATR) 0.51 0.18
MACD 0.21 0.01
Stochastic Oscillator 99.64 22.31

Price Performance

Historical Comparison
MNSB
RCEL

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: